Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related DNDN
8-K From Dendron Shows Approval For Order Authorizing Sale Transaction To Valeant
Form 8-K Shows Dendreon Debtors Determined Not To Select Stalking Horse Bid
Related FTEK
10 Stock's Moving In Monday's After-Hours Session
Fuel Tech Misses Revenue Estimates

Pre-open movers US stock futures are higher this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average surged 33 points to 13,034.00 and S&P 500 index futures rose 2.90 points to 1,383.40. Nasdaq 100 futures gained 8.25 points to 2,644.00.

A Peek Into Global Markets European markets were mixed today. The STOXX Europe 600 Index fell 0.26%, French CAC 40 index rose 0.12%. London's FTSE 100 Index moved down 0.40% and German DAX 30 index gained 0.55%.

Asian markets ended mostly higher, with Japan's Nikkei Stock Average rising 0.69%, China's Shanghai Composite dropping 0.30% and Australia's S&P/ASX 200 moving up 0.53%. Hong Kong's Hang Seng index gained 1.08% and India's Sensex jumped 0.54%.

Broker Recommendation Analysts at JPMorgan downgraded Dendreon (NASDAQ: DNDN) from “overweight” to “neutral.” The target price for Dendreon has been lowered from $15 to $6.

Dendreon shares dropped 17.48% to $5.10 in pre-market trading.

Breaking news

  • Fuel Tech (NASDAQ: FTEK) today announced receipt of multiple air pollution control orders totaling $4.5 million. To read the full news, click here.
  • Astronics (NASDAQ: ATRO) today announced that it has acquired privately-held Max-Viz Inc, a market-leading developer and designer of Enhanced Vision Systems (EVS) for fixed and rotary wing aircraft through both OEM and aftermarket channels in the general aviation, commercial and military aerospace markets for $10 million in cash. To read the full news, click here.
  • Acacia Research (NASDAQ: ACTG) announced today that its Program Rewards Solutions LLC subsidiary entered into a settlement agreement with Citigroup Inc. To read the full news, click here.
  • NuPathe (NASDAQ: PATH) today announced that the company's New Drug Application (NDA) resubmission for its migraine patch (NP101) has been accepted for filing by the U.S. Food and Drug Administration (FDA). To read the full news, click here.

Posted-In: JPMorgan US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (ACTG + ATRO)

View Comments and Join the Discussion!

Partner Center